Maralixibat chloride
Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.Maralixibat was approved for medical use in the United States in September 2021.

History
Maralixibat was granted orphan drug designations in 2013, and in 2020.

Society and culture
Legal status
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Livmarli, intended for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The applicant for this medicinal product is Mirum Pharmaceuticals International B.V.

Names
Maralixibat chloride is the international nonproprietary name (INN).

References
External links
"Maralixibat". Drug Information Portal. U.S. National Library of Medicine.
"Maralixibat chloride". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT02160782 for "Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)" at ClinicalTrials.gov